Form 4: Chromocell Therapeutics CEO Increases Indirect Ownership Through Trust Purchases

Francis Knuettel II, CEO of Chromocell Therapeutics, reports purchases of common stock through the Lara Knuettel Revocable Trust.

Summary

• On September 12, 2024, the Lara Knuettel Revocable Trust purchased 1,700 shares of Chromocell Therapeutics Corp common stock at a weighted average price of $0.97 per share.
• On September 13, 2024, the Lara Knuettel Revocable Trust purchased an additional 3,500 shares of Chromocell Therapeutics Corp common stock at a weighted average price of $0.97 per share.
• Following these transactions, the Lara Knuettel Revocable Trust beneficially owns 547,710 shares.
• Francis Knuettel II is a co-trustee of the Lara Knuettel Revocable Trust and has individual dispositive power.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects insider buying, which can be seen as positive, but it's a relatively small transaction and doesn't provide strong evidence of a bullish outlook.

Positives

• The CEO's indirect purchase of shares could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of insiders.

Stakeholder Impact

• The increased ownership by a key executive could positively influence investor sentiment.

Key Dates

Keywords

Chromocell Therapeutics, Francis Knuettel II, Lara Knuettel Revocable Trust, insider trading, beneficial ownership, Form 4, stock purchase